LAW – Page 6 – Talk Bio

Actionable Insights Powered by AI

Gritstone Bio Files for Chapter 11 Bankruptcy, Casting Uncertainty Over Cancer Vaccine Development

11 months ago talkbio0Tagged Cancer Vaccines, Chapter 11, Clinical Trials, development aspects, financial restructuring, Gritstone Bio, Immunotherapy, Vaccines

Gritstone Bio, Chapter 11 bankruptcy, cancer vaccine, financial restructuring, clinical trials, immunotherapy, vaccine development.

Gritstone Bio Files for Chapter 11 Bankruptcy, Seeks Strategic Alternatives to Preserve Clinical Research

11 months ago talkbio0Tagged Chapter 11, Clinical Research, Communicable Diseases, development aspects, Gritstone Bio, Neoplasms, strategic alternatives, Vaccines

Gritstone Bio, Chapter 11 bankruptcy, strategic alternatives, clinical research, vaccine development, oncology, infectious diseases

Travere Therapeutics Pauses Phase 3 HARMONY Study Due to Manufacturing Scale-Up Challenges

11 months ago talkbio0Tagged Homocystinuria, Manufacture, Pegtibatinase, Phase 3 HARMONY Study, Problem, scale-up

Travere Therapeutics, Phase 3 HARMONY Study, Pegtibatinase, Classical Homocystinuria, Manufacturing Scale-Up Issue

Pfizer’s Next Challenge: Phase 3 Trials for Breakthrough Cancer Therapies

11 months ago talkbio0Tagged Cancer Therapeutic Procedure, Clinical Trials, Oncology Pipeline, Pfizer, Phase 3 trials

Pfizer, Phase 3 trials, cancer therapies, oncology pipeline, clinical trials

Lantheus’ Phase 3 SPLASH Trial Results: 177Lu-PNT2002 Shows Promise but May Not Overtake Pluvicto

11 months ago talkbio0Tagged Congress (U.S. Legislature), ESMO, Lantheus, Phase 3 SPLASH, Pluvicto, PSMA, PSMA-positive metastatic castration-resistant prostate cancer

Lantheus, Phase 3 SPLASH Trial, 177Lu-PNT2002, PSMA-positive metastatic castration-resistant prostate cancer, ESMO Congress 2024, Pluvicto

ESMO 2024: IO Biotech’s IO102-IO103 Vaccine in Combination with Pembrolizumab Shows Promising Results in Head and Neck Cancer

11 months ago talkbio0Tagged biotech, Cancer of Neck, Congress (U.S. Legislature), ESMO, Immunotherapy, Io satellite, IO102-IO103, Keytruda, pembrolizumab, Therapeutic Cancer Vaccine

IO Biotech, IO102-IO103, Pembrolizumab (Keytruda), Head and Neck Cancer, ESMO Congress 2024, Therapeutic Cancer Vaccine, Immunotherapy

Novo Nordisk’s GLP-1 Agonist Demonstrates Significant BMI Reduction in Children Aged 6-12 in Phase 3 Trial

12 months ago talkbio0Tagged agonists, Body mass index procedure, Glucagon-Like Peptide 1, liraglutide, Nordisk, Obesity, Pediatric brand name, Phase 3 trial, semaglutide

GLP-1 agonists, obesity, weight loss, liraglutide, semaglutide, pediatric obesity, BMI reduction, Novo Nordisk, Phase 3 trial.

Promising Phase 2 Results for Ifinatamab Deruxtecan in Small Cell Lung Cancer

12 months ago talkbio0Tagged Cell Lung Cancer, Daiichi, Deruxtecan, ifinatamab, Phase 2 trial, Sankyo, Small, Technology, therapeutic autologous dendritic cells

Ifinatamab Deruxtecan, Small Cell Lung Cancer, Phase 2 Trial, ADC Technology, Daiichi Sankyo, Merck

Recursion’s Phase 2 Trial for Cerebral Cavernous Malformation Shows Limited Efficacy Despite Meeting Safety Goals

12 months ago talkbio0Tagged Cavernous Hemangioma of Brain, Effectiveness, Meetings, Phase 2 trial, REC-994, Recursion, Safety, tolerability, United States Food and Drug Administration

Recursion Pharmaceuticals, Phase 2 trial, cerebral cavernous malformation (CCM), REC-994, safety and tolerability, efficacy data, FDA meeting

Alnylam’s Vutrisiran Shows Promise in ATTR-CM Treatment, but Faces Competition

12 months ago talkbio0Tagged Alnylam, Amyloidosis, ATTR-CM, Cardiomyopathies, HELIOS-B, Phase 3 trial, RNA Interference, vutrisiran

Alnylam, Vutrisiran, ATTR-CM, Phase 3 Trial, HELIOS-B, RNAi Therapeutics, Cardiomyopathy, Amyloidosis